ANNUAL REPORT
2009 / 2010

GenomeQuébec

VISION

To put genomics at the heart of the scientific and socioeconomic development of Québec.

MISSION

Through the partnerships with key players in life sciences on national and international levels, Génome Québec contributes to strengthening the competitiveness of the system for innovation in genomics. The objective is to maximize the socioeconomic impact in Québec, by funding major genomics research initiatives and putting in place the tools necessary for scientific and strategic development in the field.

VALUES

Our values, here and now

- **Integrity**
  - Abiding by the rules and acting accordingly
  - Honouring one's commitments
  - Being accountable and accepting responsibility
- **Cooperation (partners and colleagues)**
  - Building relationships based on respect
  - Creating conditions conducive to commitment
  - Supporting teamwork as a mean of reaching objectives
- **Innovation**
  - Adopting better ways of doing things to achieve superior results
  - Promoting simple and useful solutions
  - Anticipating the impacts of planned changes

Corporate Information

For more information, please contact the Public Affairs and Communications Department at 514 398-0668 or Louise Thibault by e-mail at lthibault@genomequebec.com

Head office Génome Québec • 630 René-Lévesque Blvd. West, Suite 2660, Montréal, Québec H3B 1S6 • Tel.: 514 398-0668 • Fax: 514 398-0883 • E-mail: gqinfo@genomequebec.com • www.genomequebec.com

Auditors KPMG LLP • 600 de Maisonneuve Blvd. West, Suite 1500, Montréal, Québec H3A 0A3 • www.kpmg.ca

Legal adviser Me Jean Brunet • Stein Monast, S.E.N.C.R.L. • 70 Dalhousie St., Suite 300, Québec, Québec G1K 4B2

Génome Canada • 150 Metcalfe St., Suite 2100, Ottawa, Ontario K2P 1P1 • www.genomecanada.ca

Ministère du Développement économique, de l'Innovation et de l'Exportation du Québec • 710 Place D'Youville, 3rd Floor, Québec, Québec G1R 4Y4 • www.mdeie.gouv.qc.ca

McGill University and Génome Québec Innovation Centre • 740 Docteur-Penfield Ave., Montréal, Québec H3A 1A4 • Tel.: 514 398-7211 • Fax: 514 398-1790 • E-mail: infoservices@genomequebec.com

Génome Québec and Université de Sherbrooke RNomics Centre • 3201 Jean-Mignault St., Sherbrooke, Québec J1E 4K8 • Tel.: 514 398-7211 • E-mail: infoservices@genomequebec.com

Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank • 305 St-Vallier St., Chicoutimi, Québec G7H 5H6 • Tel.: 514 398-7211 • E-mail: infoservices@genomequebec.com

Génome Québec, Université de Montréal and CHUM National Immune Monitoring Laboratory (NIML) • 2350 Cohen St., Montréal, Québec H4R 2N6 • Tel.: 514 398-7211 • E-mail: infoservices@genomequebec.com

ISBN 978-2-9811988-0-8
Dépôt légal - Bibliothèque et Archives nationales du Québec, 2010
Dépôt légal - Bibliothèque et Archives Canada, 2010

Thanks to our partners

Développement économique, Innovation et Exportation Québec

GenomeCanada

MESSAGE FROM THE CHAIRMAN OF THE BOARD
Génome Québec

"Through its ongoing efforts and strategic choices, Génome Québec has significantly bolstered Québec's competitiveness in genomics and fostered the introduction of conditions that have enabled Québec to take its place as a world leader in the field."

As it celebrates its 10th year anniversary this June 29, Génome Québec can be proud of its achievements and contributions to the growth of genomics in Québec. Since it was founded, Génome Québec has channelled and administered $455 million in funding to support 40 major research projects and establish five prominent technological centres. Considered in person-years[1], this amounts to 671 researchers that have been trained and 2,170 jobs that have been created.

Through its ongoing efforts and strategic choices, Génome Québec has significantly bolstered Québec's competitiveness in genomics and fostered the introduction of conditions that have enabled Québec to take its place as a world leader in the field.

I would like to underscore the substantial exploits of those who laid the plans for Génome Québec's creation over 10 years ago, as well as the unflagging efforts of everyone involved in building a stalwart institution of which every *Québécois* can be proud. Among them are the members of the Board and Génome Québec's management and employees who spent the past decade striving to ensure our ongoing development and expansion.

Today Génome Québec is focused on planning its future, and in this regard, I wish to highlight the outstanding work of our Management Committee and employees. Over the past year, they have prepared a new 2010-2015 strategic plan centred around a vision, values and principles that are clear and fundamental. Lastly, I wish to thank my colleagues on the Board of Directors, among them Jean-Marc Proulx, our President and CEO, for their unwavering support and exceptional concern for Génome Québec's sound governance.

Gérald A. Lacoste
Chairman of the Board

[1] A person-year is a unit of measure corresponding to the work done by one person during a year, on a full-time basis.

MESSAGE FROM THE PRESIDENT AND CEO
Génome Québec

"We have introduced an organizational culture and a structure that are rooted in rigour, openness and respect for our partners."

For Génome Québec, 2009-2010 was a transformative year. Our team, in synergy with our Board of Directors, rallied together to review our practices and keep our organization in step with the realities of genomics in Québec.

We strengthened our communications with our stakeholders: researchers, universities and government bodies. We also reviewed our operations and instituted processes to ensure that we meet the highest standards of governance and management while providing the flexibility so essential to the vitality of genomics. Briefly, we introduced an organizational structure and a culture rooted in rigour, openness and respect for our partners.

We also gave careful thought to the challenges facing genomics in Québec, specifically with regard to research funding, and listened carefully to the scientific community and funding parties in order to understand their particular requirements. As a result, we were able to formulate an ambitious action plan that is nevertheless adapted to the current economic climate. Through our endeavours, we secured $30 million from the Ministère du Développement économique, de l'Innovation et de l'Exportation and launched four new research support programs.

I would like to take this opportunity to highlight the excellent performance of CARTaGENE and of the McGill University and Génome Québec Innovation Centre. CARTaGENE has demonstrated its ability to meet its objectives within the allotted timeframe, recruiting close to 9,000 participants in a mere nine months. The Innovation Centre, in turn, boosted its client pool by 10% while maintaining a high customer satisfaction level. Accessible to scientists from Québec and elsewhere, these two infrastructures are major assets for genomics in Québec, contributing to its influence and competitiveness.

While the past year primarily reflected our organization's immediate concerns, next year promises to be forward-looking, as we prioritize the implementation of our 2010-2015 strategic plan. This plan will focus on three areas: competitiveness, cooperation and integration. Moreover, it will define the role that Génome Québec intends to play with regard to other Québec stakeholders in the field of genomics, namely that of a catalyst able to create conditions to further advance genomics and its ongoing contribution to Québec's socioeconomic development.

Because the challenges inherent to genomics are in constant flux, our success as a catalyst will rest on our ability to remain attuned to our partners' needs and adapt to changes in the genomics environment. Our sustainability depends on it. More than a century ago, Darwin proclaimed that adaptation was the key to survival–a truth still relevant today in the socioeconomic sphere.

To conclude, I wish to thank all the employees of Génome Québec, the Management Committee and the members of the Board of Directors for their invaluable contribution to our accomplishments this year, and for their unfailing enthusiasm in laying the groundwork for the future.

Jean-Marc Proulx
President and CEO

MESSAGE FROM THE VICE PRESIDENT, SCIENTIFIC AFFAIRS
Génome Québec

"The high point of our activities in 2009-2010, the launch of four new programs in support of genomics, marks the culmination of successful exchanges carried out over a period of several months with our scientific and government partners."

Last December, Génome Québec proudly unveiled four new programs in support of genomics. The high point of our activities in 2009-2010, this achievement was the culmination of successful exchanges carried out over a period of several months with our scientific and government partners. We are grateful to our scientific partners for their ongoing faith in us, and for having voiced their most urgent concerns regarding the future of genomics in Québec. To our government partners, we say thank you for having understood the importance of investing additional funds in genomics to maintain Québec's competitive advantage in this field. We are particularly grateful to the MDEIE (Ministère du Développement économique, de l'Innovation et de l'Exportation) for its grant of $30 million last October.

It had become necessary to develop new programs that would aptly reflect both the needs of the scientific community as well as Québec's strategic priorities in the areas of research and innovation. Human health, a pivotal sector of genomics, constituted the foundation of our program development. The need for new and stronger funding was in large part due to Québec's leadership position in this field. In this regard, we wanted to invest not only in research projects, but also in highly qualified human capital, a widespread approach in Europe and the United States that is not yet as popular in Canada. Lastly, we also wished to support smaller projects, some related to human health, others not.

For this reason, we are offering the Québec scientific community a wide range of financing options. Two programs are specifically designed to support research in human health genomics. The first of these seeks to further knowledge of the mechanisms, diagnostics and treatment of human diseases, while the second, increasingly accepted, is designed to favour short-term applications and support the creation of tools for improving the prediction, prevention, diagnosis and treatment of diseases. *The Recruitment Program - Human Health* will support universities in their efforts to hire researchers of international calibre specialized in genomics as applied to human health. As for the *Pilot Project Competition*, its goal is to provide researchers with the means of obtaining preliminary results and thereby improve their probability of success in national or international competitions.

The cooperative spirit underlying these programs is also a key aspect of many of our initiatives in 2009-2010. In fact, throughout the year we multiplied opportunities for working more closely than ever with the scientific community. This was notably the case during last September's two-day forum for researchers, research institutes and public agencies associated to Génome Québec, "*Tous ensemble vers un but commun*" (All together toward one goal). This orientation also led to our support for various scientific activities, some associated to the Human Proteome Organization and others to the *Réseau de médecine génétique appliquée*. The launch of our *Synergie* newsletter in the fall of 2009 stemmed from this same desire to further interact with stakeholders in Québec's genomics community. *Synergie*, published three times a year, highlights successful genomics research activities in Québec while constituting a platform for the discussion of the challenges inherent in the field.

Long a core element of Génome Québec's orientations, personalized medicine is now central to our strategy, and we are making concrete efforts to promote it, notably through concerted action with our partners, among them the *Fonds de la recherche en santé du Québec* (FRSQ), *Montréal InVivo*, the *Consortium québécois sur la découverte du médicament* (CQDM) and the *Centre of Excellence for Personalized Medicine* (CepMed), an organization founded by the Montreal Heart Institute and supported by the Canadian Government, Genome Quebec as well as private partners (Pfizer, AstraZeneca, Novartis and Merck).

Fuelled by renewed relationships with Québec genomics stakeholders as well as further investments, we are starting off the 2010-2011 year with optimism and vigour. We will be focusing our efforts on moving forward and targeting the diversification of funding sources for genomics research. We have already begun considering new competitions in partnership with provincial agencies and are also seeking to establish relationships with international consortiums, primarily ERA-NET, a European initiative that provides support for the creation of transnational networks and the coordination of research programs.

We hope that these actions will provide Québec research scientists with yet more research opportunities that will garner them exposure at a national and international level. Such achievements will prove key factors in maintaining our competitive standing in the area of genomics.

Catalina Lopez Correa
Vice President, Scientific Affairs

ABC COMPETITION

In April 2009, three projects chaired or co-chaired by Québec researchers were selected as part of Genome Canada's national Competition in Applied Genomics Research in Bioproducts or Crops (ABC). Together, these initiatives represented $26 million, or 28.5% of the total funds granted. The scientific activities associated with these projects began last October 1st and will span a period of three to four years.

As a result, Professor Adrian Tsang from Concordia University was awarded $17.4 million for his project Genozymes for Bioproducts and Bioprocesses Development. His goal? To identify mushroom proteins that play a role in the decomposition of woody biomass and produce them in sufficient quantities to support the industrial production of biofuels and other bioproducts.

The Synthetic Biosystems for the Production of High Value Plant Metabolites project, co-chaired by Professors Vincent Martin of Concordia University and Peter Facchini from the University of Calgary benefited from $13.6 million in funding, $4.6 million of which will be spent in Québec. This project aims to identify the genes and enzymatic pathways responsible for the synthesis of important chemical plant compounds, to industrially duplicate the associated processes for around 75 plants.

McGill University's Professor Thomas Bureau received $4.5 million for a project involving the identification and experimental validation of new regulatory sequences and genes for improved crops. By comparing the genomes of several close relatives of *Arabidopsis* and canola, he hopes to target non-coding DNA regions with a positive impact on Canadian agricultural productivity and yield.

In addition to these three major projects, two other Québec researchers—Richard Gold from McGill University and Lyne Létourneau from Université Laval—also obtained funding under the auspices of this competition. They were awarded $305,000 for their participation in the cross-Canada Value Addition Through Genomics and GE^{3}LS project (VALGEN), managed by Genome Prairie. Conducted by a Cross-Canada team, VALGEN seeks to determine how Canada can benefit from the application of genomics research to agriculture.

The McGill University and Génome Québec Innovation Centre is also reaping the rewards of the ABC Competition, as eight projects from Québec and elsewhere in Canada will be drawing on its technological services to the tune of nearly $6 million in revenues. Such an achievement attests to the Innovation Centre's reputation and its ability to meet actual needs in the scientific community.

Génome Québec applauds Québec's excellent performance, a testimony to the region's high degree of competitiveness in two strategic genomics sectors, agriculture and the environment. It also wishes to congratulate the researchers whose work made this success possible and will contribute to the perfection of new green solutions, wealth creation and sustainable development.

CARTaGENE

CARTaGENE is a major group initiative established in 2007 to facilitate research on population genomics. The project's activities were spearheaded by the July 2009 launch of its phase A recruitment efforts, which sought to gather health information and biological samples from 20,000 Quebecers between the ages of 40 and 69. The project has reached nearly 44% of its target, with 8,700 participants confirmed at March 31, 2010. To further promote cooperation, CARTaGENE has increased the number of recruitment sites from 6 to 12.

The phase A activities completed thus far prove that the data acquisition and interview management procedures meet the project's stringent requirements. The transfer and storage of blood and urine samples provided by participants to the Génome Québec and Centre hospitalier universitaire régional de Chicoutimi Biobank also comply with the highest standards of excellence.

There have already been requests for access to CARTaGENE data and samples, notably from researchers at Université Laval, Queen's University and Centre hospitalier de l'Université de Montréal. The scientific community's immediate interest demonstrates the relevance of a research infrastructure such as the one being introduced by CARTaGENE.

A member of the *Canadian Partnership for Tomorrow Project* (CPTP) and the *Public Population Project in Genomics* (P^3G), CARTaGENE has worked with these organizations to facilitate the future sharing of data through the use of coherent methods and tools for greater similarity of statistical studies. Furthermore, CARTaGENE is increasingly in use at Université de Montréal, the host institution responsible for the project.

Another milestone for CARTaGENE was this year's nomination of Phillip Awadalla to the position of Scientific Director. Professor of paediatrics at Université de Montréal, he is also a researcher at CHU Sainte-Justine as well as a world-renowned expert in population genomics. Professor Awadalla's recruitment was spearheaded by Génome Québec, which allocated an amount of $2.5 million over a five-year period to enable him to develop the tools necessary for phase B of CARTaGENE, which will include the analysis of major data sets.

2010-2011 promises to be a busy and fervent period for CARTaGENE, with the project's phase A slated for completion by the end of October 2010 and phase B in its preliminary stages. The project will also begin monitoring those participants it has already met with, due in large part to the support of the CPAC (*Canadian Partnership Against Cancer*). Lastly, the project team will work in conjunction with its federal and provincial partners to develop a funding structure spanning the next three to five years.

A partner of CARTaGENE since the project's inception in 2007, Génome Québec is pleased to contribute to the initiative's success while helping to create a public population genomics resource that will make it possible to conduct more in-depth research on the relationships between genes, the environment, lifestyle and health.

SOME OF THE YEAR'S OUTSTANDING ACHIEVEMENTS

Ensuring the Future of our Forests

The Arborea II Project, begun in April 2006 by professors John MacKay and Jean Bousquet of Université Laval, is making good headway. Funded under Genome Canada's Competition III, it seeks to draw up an inventory of the genetic variability of spruce and develop tools for identifying those varieties with the best quality and growth potential. To date, nearly 30,000 major genes have been recorded with the goal of improving populations of this softwood. A catalogue of 27,720 genes of white spruce (*Picea glauca*) was published in January 2010. It constitutes one of the largest such catalogues of plant species.

Facilitating Biomarker Identification

Two new proteomics platforms were created this year, representing novel opportunities for the identification of biomarkers. These platforms were developed under a Genome Canada New Technology Development Competition project, Integrated Proteomics Platforms for High-Throughput Biomarker Discovery and Validation, led by Maryam Tabrizian of McGill University. By enabling the parallel analysis of numerous proteins with improved sensitivity and specificity, these platforms are unlike traditional proteomics tools and will make it possible to detect biomarkers that will, in their quality as disease indicators, contribute significantly to both research and diagnostics.

Understanding the Risks of Common Diseases

Year after year, the excellence and relevance of the GRID Project Gene Regulators in Disease, led by Professor Tomi Pastinen of McGill University, continue to be revalidated. Since its introduction in 2006, the project has been the subject of 66 articles in renowned scientific publications including 28 over the past year and three in the prestigious *Nature Genetics*. Selected as part of Genome Canada's Competition III, the GRID Project aims to characterize over 250 pathological genes associated with common diseases (diabetes, asthma, certain cancers, inflammatory diseases, etc.) in order to identify appropriate regulatory mechanisms. The project will further understanding of the risks of disease while paving the way for innovative treatments.

Building a Foundation for Tomorrow's Vaccines

The genomics and proteomics platforms for vaccines and immune therapeutics discovery and development project led by Professor Rafick-Pierre Sékaly of Université de Montréal made significant strides this year, with the creation of a unique high-throughput immunological monitoring platform. Integrated into the new *Génome Québec, Université de Montréal and CHUM NIML* (National Immune Monitoring Laboratory) *platform*, it facilitates the quick and accurate monitoring of immune responses and was successfully adopted by Professor Sékaly and his team to develop new tests based on the signatures associated with immune responses. Funded under Génome Québec's PRIVAC program since 2008, this major project seeks to better understand the mechanisms underlying effective immune responses in order to develop new vaccines.

MESSAGE FROM THE VICE PRESIDENT, PUBLIC AFFAIRS AND COMMUNICATIONS
Génome Québec

"Génome Québec, through rewarding exchanges with its government and academic partners, obtained in October 2009 $30 million from the MDEIE to fund genomics research. We take this to represent a significant expression of faith in what we are doing."

Génome Québec strives to take advantage of all of the opportunities available to it in order to showcase the potential contribution of genomics to Québec's socioeconomic development. The year 2009-2010 was replete with opportunities for us to speak out and promote our achievements, which we proudly did.

We participated in the consultations led by the Ministère du Développement économique, de l'Innovation et de l'Exportation (MDEIE) on the updating of the Québec Research and Innovation Strategy. We felt compelled to take part in this initiative, to ensure that the renewed Strategy, covering the 2010-2013 period, continues to view genomics as a key sector. This initiative, in fact, became one of our central priorities as of June 2009. On September 8, we submitted a position paper to the group responsible for the Québec Research and Innovation Strategy's update, which we followed up by exchanging and submitting our observations to the parties concerned.

Through productive exchanges with government and academic partners, Génome Québec secured, in October 2009, $30 million from the MDEIE to fund genomics research independently of Génome Canada's activities. This was a major expression of stakeholders' faith. Less than three months after having received these funds, we introduced four support programs for the Québec scientific community, another crowning achievement.

We also joined forces with the Arborea group and the Quebec Intensive Silviculture Network to submit a position paper to the Minister of Natural Resources and Wildlife during the consultations on Bill 57 concerning sustainable forest development. This initiative represented an opportunity to position genomics as a solution to the challenges facing the forest industry, and led to a series of ongoing discussions with the Minister, who has demonstrated interest in the Arborea project activities.

On November 12, 2009, the Government of Québec tabled Bill 67 for the creation of the *Institut national d'excellence en santé et services sociaux* (INESSS), a new agency that will replace the *Conseil du médicament* and the *Agence d'évaluation des technologies et des modes d'intervention en santé* (AETMIS), the government agency responsible for health services and technology assessment. Once again, we initiated a dialogue focused on promoting the integration of applications derived from genomics to the healthcare system. Génome Québec drafted a position paper in this regard last February.

The year 2010-2011 will see the implementation of a new Génome Québec business plan. As ever, we wish to move ahead with developing genomics in Québec. We will assess the extent of its integration, manage the associated spin-offs and strive to increase understanding. We are thus embarking on this new year with the firm intention of taking concrete action to further integrate genomics to the healthcare and natural resources sectors.

Marie-Kym Brisson
Vice President, Public Affairs
and Communications

GÉNOME QUÉBEC TECHNOLOGICAL CENTRES

In conjunction with its partners, Génome Québec in 2009-2010 supported five technological centres dedicated to making a genomics research infrastructure and state-of-the-art expertise available to the scientific community.

McGill University and Génome Québec Innovation Centre

The Innovation Centre saw its university and industrial client pool grow by 10% over the past year, with the number of clients increasing from 647 to 704. Such rapid growth attests to the Centre's renown and its success in meeting a real need of the scientific community by offering it a single window for sophisticated genomics and proteomics equipment, powerful computer tools and highly qualified personnel. The Innovation Centre conducts annual surveys of its clients, with highly telling results: 60% of new clients were referred to the Centre by satisfied colleagues. This year, in its ongoing pursuit of excellence, the Innovation Centre doubled its high-throughput sequencing capacity and instrument inventory. It is also planning to acquire third-generation technology in the near future.

Génome Québec and Montreal Heart Institute Pharmacogenomics Centre

Over the past year, the Pharmacogenomics Centre consolidated its infrastructure so as to offer high-quality services in support of research in personalized medicine. It was able to optimize its services by acquiring and implementing new technologies in DNA sequencing and analysis (Illumina Genome Analyser IIe, Affymetrix GeneChip System), automation (Tecan Freedom EVO, QIAgen QIAsymphony SP, QIAgen EZ1 Advanced) and bioinformatics support (Isilon IQ and Sun StorageTek SL3000 Tape Library).

Génome Québec and Centre hospitalier universitaire régional de Chicoutimi Biobank

As part of its activities within the framework of the major international project CARTaGENE, the Biobank has begun receiving samples from hundreds of participants from across Québec. These samples are sent to the Biobank each week for processing, divided into aliquots of various sizes and long-term storage. By the end of the year, over 100,000 aliquots had been stored at the Biobank's facilities. The technological infrastructure of the Biobank was upgraded subsequent to major investments by the ECOGENE-21 research group from *the Centre hospitalier affilié universitaire régional de Chicoutimi*, effectively doubling the availability capacity for processing samples.

Génome Québec, Université de Montréal and CHUM NIML Centre

The NIML Centre (National Immune Monitoring Laboratory) is dedicated to evaluating immune responses to test vaccines and preventive and therapeutic treatments. During its rollout phase, it focused its efforts on the development of new immune monitoring tests and control tools. The NIML Centre has entered into four separate service agreements with major pharmaceutical companies, which together represent contracts valued in the millions.

Génome Québec and Université de Sherbrooke RNomics Centre

The RNomics Centre offers unique technology and expertise in the analysis and validation of RNA splicing and gene expression. The majority of its activities in 2009-2010 consisted of supporting the Functional Annotation of Essential Alternatively Spliced Isoforms project led by Sherif Abou Elela from Université de Sherbrooke and funded under Genome Canada's Competition III.

COMMUNICATION AND EDUCATIONAL ACTIVITIES

This year's communication objectives were two-fold: to strengthen Génome Québec's acquired knowledge and to launch new educational projects.

To meet these objectives, the communications team revamped our Web site to sharpen its focus on the requirements of the scientific community as well as on research imperatives. The team instituted a number of initiatives to enhance the site and make it a more relevant resource and reference tool, including daily updates on new developments in genomics in Québec and a press review on the work of researchers in the "Researchers in the News" section.

"*Genomics: A Revolution Has Begun*" is a communication and reference tool consisting of a genomics booklet that presents an overview of our activity sector. It has been such a resounding success this year that we will be producing a new edition featuring updated data and images.

As for our educational objective, we are proud to announce a significant, innovative achievement: the creation of the online game *Genomia*. Available free of charge thanks to the financial support of the MDEIE, *Genomia* was developed in conjunction with experts in the area of ludopedagogical multimedia games and high school and Cégep teachers. It was introduced and made available online during the Eurêka! Festival held in Montréal from June 12 to 14, 2009. Over 400 youths visited our kiosk at the Festival site in Old Montréal and to date, nearly 15,800 Internet visitors have discovered genomics by playing the online game.

This project allowed Génome Québec to make great strides by using a game environment to effectively reach and appeal to a target public with a generally short attention span for all matters scientific.

Given Génome Québec's constant concern for raising students' awareness of science, we play an active role in numerous scientific events such as the Sanofi-Aventis BioTalent Challenge. For the past eight years, we have also been associated with Expo-Sciences, which celebrated its 50th anniversary this year, without a doubt one of the most prominent events in which Génome Québec is involved.

Photo credit: Terry Charland

During the 2009 *Super Expo-science Bell*, Catalina Lopez Correa, Vice President, Scientific Affairs, presented the Génome Québec award to Alexandre Lemieux from Externat Saint-Jean-Eudes, Québec City.

Lastly, we are extremely pleased with our decision to participate, for the first time, in the International Economic Forum of the Americas where we presented conferences on genomics. The event was attended by nearly 200 people, including a number of key socioeconomic stakeholders. The experience allowed us to meet one of our objectives, namely increasing knowledge of the major issues associated with genomics in the economic, political and public spheres. In light of the event's success, we will be partnering with the Forum again this year, enhancing our involvement through the cooperation of key partners in the area of personalized medicine (CepMed and Montréal InVivo).

HUMAN RESOURCES

During the past year, Génome Québec undertook to identify key values for the organization which would foster the commitment and contribution of officers, executives and employees while guiding them in their actions and decision-making.

Adopted during a December 15, 2009 Board of Directors meeting, these values are integrity, cooperation and innovation.

- Integrity implies our abiding by the rules in all of our actions, honouring our commitments, acting responsibly and remaining accountable.
- Innovation, in turn, involves achieving superior performance by improving how we do things, favouring simple and useful solutions, and taking the impacts of proposed changes into account.
- Cooperation consists of creating the conditions necessary to ensure the commitment of colleagues and partners, maintaining relationships with them based on mutual respect, and working as a team to achieve desired results.

These values were presented and discussed internally on two separate occasions, with managers on January 20, 2010, and again on February 10, 2010, this time with all Génome Québec employees. The reaction was very favourable on both occasions.

Our challenge next year will revolve around concretely instilling these new values in all of our daily actions, with managers urging employees to take ownership of these values and apply them consistently while seeking to meet their respective objectives.

MESSAGE FROM THE VICE PRESIDENT, FINANCE AND INVESTMENTS
Génome Québec

"Our actions in 2009-2010 had a specific purpose: observing the best management and governance practices for optimal use of the resources destined to the development of genomics in Québec."

The activities of our Finance department in 2009-2010 reflect Génome Québec's desire to infuse new energy into its partnerships with genomics actors while overseeing the efficiency of its internal processes and structures.

As a result, we restructured the technological centres. Shared services were introduced to provide a framework for relationships with clients as well as the Legal, Human Resources and Finance departments, and we also worked with host institutions to review all of the applicable business models. The new model supports the authority of each centre's scientific management over its development. Consequently, Génome Québec's role will now focus on sustaining the creation of value-added services.

We also collaborated with various stakeholders to conclude research funding agreements. More specifically, our department prepared subsidy agreements governing the reallocation of funds received from the Ministère du Développement économique, de l'Innovation et de l'Exportation (MDEIE) and Genome Canada. These agreements concern Québec projects and researchers receiving financial support as part of Genome Canada's Competition in Applied Genomics Research in Bioproducts or Crops (ABC) or under the new research programs launched by Génome Québec last December.

During the course of the year, Génome Québec underwent its four-year MDEIE evaluation for the period from April 1, 2005 to March 31, 2009, an ongoing process that allowed us to benchmark and conduct a detailed analysis of our results and approaches over the long term. This exercice was conducted with the MDEIE in an excellent collaborative spirit and we are confident of the upcoming results.

Our department's other main activities mostly involved operations monitoring and improvement. We continued reducing our general administrative expenses, which were 30% lower compared to the previous fiscal year, and ensured the effectiveness of our control mechanisms with respect to governance and risk management. With a view to ongoing optimization, we also updated our computer infrastructure by replacing all of our servers.

Our actions in 2009-2010 had a specific purpose: observing the best management and governance practices for optimal use of the resources destined to the development of genomics in Québec. This same purpose will guide our priorities for the coming year.

2010-2011 PRIORITIES

- Participate in the development of our 2010-2015 strategic plan and ensure its implementation.
- Move forward with the optimization of our key processes.
- Support funding for research within the framework of future Genome Canada competitions.

Raymond Castonguay
Vice President, Finance and Investments

FINANCIAL ACTIVITY REPORT
Génome Québec

As at March 31, 2010, our portfolio included 20 genomics and proteomics projects, for a total budget of $168 million. Génome Québec invested $45.2 million during the 2009-2010 fiscal year. This amount, combined with the $28.8 million invested by other partners in major research projects, brings our overall injection of funds to $74.0 million.

Genome Canada and Québec's Ministère du Développement économique, de l'Innovation et de l'Exportation (MDEIE) are Génome Québec's main funding agencies.

Business volume from major projects increased over the course of the fiscal year, to reach $56.6 million. This is in large part due to the acknowledgement of our international partners' investment in the P³G/CARTaGENE project. In spite of this increase, numerous Competition III and PRIVAC projects are completed or nearly so. Technological Development Competition projects reached their cruising speed in 2009-2010, and activities under the ABC Competition project were launched during this same period.

For the year ended at March 31, 2010, a fifth technological centre, the NIML (National Immune Monitoring Laboratory), joined the ranks of our four other technological centres. Their combined sales were $13.6 million, a drop of 15% from the previous year. This decrease is primarily due to a decline in sales from Competition III projects as well as certain of the innovation centre's university clients. The technological centres posted an excess of revenue over expenses of $0.9 million. Of this total, $0.6 million was added to restricted net assets and $0.3 million to unrestricted net assets during the exercise.

General and administrative expenses totalled $3.5 million for the fiscal year, or 4.8% of total investments. These expenses were $3.9 million (adjusted for certain centre expenditures and non-recurring expenditures) or 6.6% the previous year. Expenses associated to hospitality, travel expenses, professional fees and office expenses were all lowered. Interests reached $447,634, for a return of 2.6%.

During the fiscal year, the excess of revenue over expenses totalled $0.9 million. Unrestricted net assets rose by $996,000, for a total of $1.7 million. Unrestricted net assets represent a possible source of funding for future activities in keeping with Génome Québec's strategic development plans.

Génome Québec met the obligations and milestones provided for in its contractual agreements with major financial partners.

Jean-Marc Proulx
President and CEO
Génome Québec

Raymond Castonguay
Vice President, Finance and Investments
Génome Québec

GÉNOME QUÉBEC AND PARTNERS 2009-2010



GÉNOME QUÉBEC AND ACTIVITIES
Total investment of $74.0M



AUDITORS' REPORT TO THE DIRECTORS
Génome Québec

We have audited the statement of financial position of Génome Québec as at March 31, 2010 and the statements of operations, changes in net assets and cash flows for the year then ended. These financial statements are the responsibility of the Corporation's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

In our opinion, these financial statements present fairly, in all material respects, the financial position of the Corporation as at March 31, 2010 and the results of its operations and its cash flows for the year then ended in accordance with Canadian generally accepted accounting principles.

KPMG LLP*

Chartered Accountants
Montréal, Canada
May 21, 2010

*CA Auditor permit no 14553

STATEMENT OF FINANCIAL POSITION

March 31, 2010, with comparative figures for 2009

	2010	2009
Assets		
Current assets:		
Cash and cash equivalents	$1,411,970	$2,572,420
Short-term investments	13,755,300	6,311,973
Accounts receivable and work in progress	1,607,579	2,257,458
Contribution receivable	—	2,065,872
Advances to genomic research projects	187,301	687,345
Inventories	663,605	1,164,428
Prepaid expenses	662,345	796,932
	18,288,100	15,856,428
Long-term investments (note 3)	10,341,635	14,947,232
Capital assets (note 4)	1,517,848	4,186,646
	$30,147,583	$34,990,306
Liabilities and Net Assets		
Current liabilities:		
Accounts payable and accrued liabilities	$3,850,892	$3,508,014
Deferred revenues	170,777	195,741
Contributions to be reimbursed (note 5 [1])	1,348,170	1,348,170
	5,369,839	5,051,925
Deferred contributions:		
Future expenses (note 5)	20,346,136	23,875,203
Capital assets (note 6)	1,222,894	3,792,392
	21,569,030	27,667,595
Net assets:		
Unrestricted	1,720,654	724,671
Restricted – invested in capital assets (note 4)	294,954	394,254
Restricted – Technology investment and contingency fund	1,193,106	1,151,861
	3,208,714	2,270,786
Commitments (note 9)		
Subsequent event (note 10)		
	$30,147,583	$34,990,306

See accompanying notes to financial statements.

On behalf of the Board:

_____, Director

_____, Director

STATEMENT OF OPERATIONS

Year ended March 31, 2010, with comparative figures for 2009

	2010	2009
Revenues:		
Amortization of deferred contributions related to expenses (note 5)	$35,116,000	$32,761,660
Amortization of deferred contributions related to capital assets (note 6)	3,628,574	2,433,359
Investment income (note 7)	688,704	826,429
Revenues from technology centers	13,605,360	15,915,953
Revenues from intellectual property and others (note 7)	204,657	—
	53,243,295	51,937,401
Expenses:		
Genomic research projects	27,767,914	24,646,814
Technology centers operational cost	15,807,333	18,347,570
Projects - Technology investment and contingency fund	553,841	89,427
General and administrative	3,216,784	4,566,285
Strategic initiatives	1,160,424	302,036
Depreciation of capital assets	3,628,574	2,433,359
Depreciation of restricted capital assets	170,497	118,917
	52,305,367	50,504,408
Excess of revenues over expenses	$937,928	$1,432,993

See accompanying notes to financial statements.

STATEMENT OF CHANGES IN NET ASSETS

Year ended March 31, 2010, with comparative figures for 2009

				2010
	Restricted		Unrestricted	Total
	Invested in capital assets	Technology investment and contingency fund		
Net assets, beginning of year	$394,254	$1,151,861	$724,671	$2,270,786
Excess of revenues over expenses (expenses over revenues)	(170,497)	645,269	463,156	937,928
Invested in capital assets	71,197	(50,183)	(21,014)	—
Invested in projects – Technology investment and contingency fund	—	(553 841)	553 841	—
Net assets, end of year	$294,954	$1,193,106	$1,720,654	$3,208,714

				2009
	Restricted		Unrestricted	Total
	Invested in capital assets	Technology investment and contingency fund		
Net assets, beginning of year	$390,035	$172,672	$275,086	$837,793
Excess of revenues over expenses (expenses over revenues)	(118,917)	1,191,752	360,158	1,432,993
Invested in capital assets	123,136	(123,136)	—	—
Invested in projects – Technology investment and contingency fund	—	(89,427)	89,427	—
Net assets, end of year	$394,254	$1,151,861	$724,671	$2,270,786

See accompanying notes to financial statements.

STATEMENT OF CASH FLOWS

Year ended March 31, 2010, with comparative figures for 2009

	2010	2009
Cash flows from operating activities:		
Excess of revenues over expenses	$937,928	$1,432,993
Adjustments for:		
Depreciation of capital assets	3,799,071	2,552,276
Amortization of deferred contributions related to expenses (note 5)	(35,116,000)	(32,761,660)
Amortization of deferred contributions related to capital assets (note 6)	(3,628,574)	(2,433,359)
	(34,007,575)	(31,209,750)
Contributions received	32,646,009	39,240,617
Changes in assets and liabilities:		
Accounts receivable and work in progress	649,879	(42,834)
Contribution receivable	2,065,872	(2,065,872)
Advances to genomic research projects	500,044	452,400
Inventories	500,823	(440,929)
Prepaid expenses	134,587	(372,523)
Accounts payable and accrued liabilities	342,878	(127,853)
Deferred revenues	(24,964)	(1,465,356)
Contributions to be reimbursed	—	(1,058,076)
	4,169,119	(5,121,043)
	2,807,553	2,909,824
Cash flows from investing activities:		
Change in short-term investments	(7,443,327)	12,060,813
Change in long-term investments	4,605,597	(14,947,232)
Purchase of capital assets	(1,130,273)	(1,747,975)
	(3,968,003)	(4,634,394)
Net decrease in cash and cash equivalents	(1,160,450)	(1,724,570)
Cash and cash equivalents, beginning of year	2,572,420	4,296,990
Cash and cash equivalents, end of year	$1,411,970	$2,572,420

Additional information (note 7)

See accompanying notes to financial statements.

NOTES TO FINANCIAL STATEMENTS
Year ended March 31, 2010

Génome Québec (the "Corporation") was incorporated on June 29, 2000 under Section II of the Canada Corporations Act. Génome Québec is a not-for-profit organization and has the following objectives:

a) to develop and maintain in the province of Quebec a coordinated approach and an integrated strategy in the fields of genomic research (including health, agriculture, environment, forestry and fisheries) by bringing together the intervening parties from the industry, governments, universities, research centers and laboratories, as well as any other person or organization interested in advancing the goals of the Corporation;

b) to create, operate and support an infrastructure network in genomics giving Quebec researchers access to a high technology expertise;

c) to ensure that researchers have access to the necessary equipment and installations to undertake research and development projects in genomics, and to allow for the training of researchers and technologists;

d) to raise the awareness of the population to the necessity of research in genomics, to the usefulness and consequences of the outcome from this research, to ensure an ethical environment for the researchers and to contribute to public awareness regarding the stakes involved in genomic research.

1. Significant accounting policies:

a) Cash and cash equivalents:
Cash and cash equivalents consist of cash as well as all highly liquid short-term investments which have a maturity of less than three months from the date of acquisition.

b) Investments:
Short-term investments and long-term investments, redeemable at any time, are recorded at the market value.

c) Work in progress:
Work in progress is recorded at the pro rata billing value of the work completed.

d) Inventories:
Inventories are represented by supplies which will be utilized by the technology centers. The supplies are recorded at the lower of cost and net realizable value. The cost is determined using the first in, first out method.

e) Advances and charges related to genomic research projects:
The advances represent the excess of the contributions to the research projects, including work performed by the technology centers, over the claims received which are recognized in the statement of operations.

f) Revenue recognition:
The Corporation follows the deferral method of accounting for contributions which include mainly funding from Genome Canada and the ministère du Développement économique, de l'Innovation et de l'Exportation du Québec. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

NOTES TO FINANCIAL STATEMENTS (continued)
Year ended March 31, 2010

f) Revenue recognition (continued):
Externally restricted contributions are recognized as revenue in the year in which the related expenses are incurred. Restricted contributions related to the purchase of capital assets are deferred and amortized to revenues using the same methods and rates of the related capital assets.

Revenues from technology centers are sequencing, genotyping, biochip, biological sample storage, proteomics services and high throughput immunomonitoring lab tests. Revenues are recognized on the basis of the services rendered.

g) Capital assets:
Capital assets are stated at cost. Depreciation is provided for using the following methods, period and annual rates:

Asset	Method	Period/rate
Furniture and fixtures	Declining balance and straight-line	20% and 4 years
Equipment	Declining balance and straight-line	30% and term of project and 4 years
Computers and software	Declining balance and straight-line	30% and 3 years

h) Financial instruments:
All financial instruments are classified into one of the following five categories: held-for-trading, held-to-maturity investments, loans and receivables, available-for-sale financial assets or other financial liabilities. All financial instruments are included in the balance sheet and are measured at fair market value, with the exception of loans and receivables, investments held-for-maturity and other financial liabilities, which will be measured at amortized cost. Subsequent measurement and recognition of changes in fair value of financial instruments depend on their initial classification.

Held-for-trading financial investments are measured at fair value, and all the gains and losses are included in net income in the period in which they arise. Available-for-sale financial instruments are measured at fair value with revaluation gains and losses included in other comprehensive income until the asset is removed from the balance sheet. The Corporation has classified its short-term and long-term investments as "held-for-trading" and they are accounted for at fair value. The Corporation has classified its accounts receivable and work in progress, contribution receivable and advances to genomic research projects as loans and receivables and its accounts payable and accrued liabilities as other financial liabilities which are measured at amortized cost.

i) Use of estimates:
The preparation of financial statements in conformity with generally accepted accounting principles requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Significant areas requiring the use of management's estimates relate to the determination of the useful life and the estimated residual value of the capital assets along with the recoverability of long-term investments. Accordingly, actual results could differ from those estimates.

NOTES TO FINANCIAL STATEMENTS (continued)
Year ended March 31, 2010

2. Restricted net assets:

Under agreements, the excess of revenues over expenses generated by these technology centers includes restrictions for its reinvestment:

For the pharmacogenomics center, for the first four years ended March 31, 2010, the first $1,330,000 of excess must be reinvested in the center to insure its development. As at March 31, 2010, the excess amounts to $692,518.

For the RNomics center, the excess must reimburse Génome Québec's financial contribution towards the start-up costs. As at March 31, 2010, the start-up costs total $517,681.

For the Innovation center, a technology investment and contingency fund has been established to implement new technologies and pay for other expenses incurred by the center. The contributions represent a percentage of the revenues generated from services rendered to Genomics research projects and Canadian academics. As at March 31, 2010, the net assets total $215,500.

For the NIML center, the excess of the first operating year must be reinvested in the center as technology investment and contingency fund. As at March 31, 2010, the net assets total $285,088.

3. Long-term investments:

	2010	2009
Bonds, provincials and municipals, with a yield at cost, considering that the bond is held to maturity, between 1.74% and 2.77%, and a maturity ranging from April 2011 to August 2012	$10,341,635	$14,947,232

4. Capital assets:

			2010	2009
	Cost	Accumulated depreciation	Net book value	Net book value
Furniture and fixtures	$266,109	$243,784	$22,325	$82,860
Equipment – technology centers	5,777,601	4,776,831	1,000,770	1,480,401
Equipment – restricted assets – technology centers	653,197	358,243	294,954	394,254
Equipment – research projects	11,959,968	11,959,968	—	1,916,641
Computer and software	657,526	457,727	199,799	312,490
	$19,314,401	$17,796,553	$1,517,848	$4,186,646

NOTES TO FINANCIAL STATEMENTS (continued)
Year ended March 31, 2010

5. Deferred contributions related to future expenses:

The Corporation receives contributions from Genome Canada and the ministère du Développement économique, de l'Innovation et de l'Exportation du Québec. These contributions will be administered and distributed in accordance with the terms and conditions of the related agreements.

Deferred contributions related to expenses of future periods represent the unspent externally restricted funding for the purposes of providing contributions to eligible recipients and paying operating and capital expenditures in future periods.

The deferred contributions are:

	Balance March 31, 2008	2009 Transactions	Balance March 31, 2009	2010 Transactions	Balance March 31, 2010
Contributions:					
Genome Canada	$138,760,301	$16,919,810	$155,680,111	$20,731,817	$176,411,928
Government of Québec	122,482,617	20,727,871	143,210,488	10,941,017	154,151,505
Canada Economic Development	431,829	1,114,260	1,546,089	583,911	2,130,000
VRQ	3,760,560	—	3,760,560	—	3,760,560
Cancer Care Ontario	3,113,815	478,398	3,592,213	389,264	3,981,477
Genome Prairies	1,947,093	—	1,947,093	—	1,947,093
FQRNT	500,000	—	500,000	—	500,000
FRSQ	439,000	—	439,000	—	439,000
MSSS	100,000	—	100,000	—	100,000
Other	71,851	—	71,851	—	71,851
Natural resources	100,000	—	100,000	—	100,000
	271,707,066	39,240,339	310,947,405	32,646,009	343,593,414
Investment income	2,871,270	—	2,871,270	—	2,871,270
Reclassification of completed projects (i)	(3,104,904)	278	(3,104,626)	—	(3,104,626)
Recovery of taxes on goods and services (ii)	905,557	—	905,557	—	905,557
Amount amortized to revenues	(234,778,634)	(32,761,660)	(267,540,294)	(35,116,000)	(302,656,294)
Amount invested in capital assets	(18,579,270)	(1,624,839)	(20,204,109)	(1,059,076)	(21,263,185)
	$19,021,085	$4,854,118	$23,875,203	$(3,529,067)	$20,346,136

(i) The financial support of many research projects and current and capital expenses related to Competitions I, II and the Applied Genomics and Proteomics Research in Human Health ended on March 31, 2009. Contributions received in excess of the related accumulated expenses are reclassified as contributions to be reimbursed.

(ii) The Corporation received an opinion from the tax authorities allowing the recovery of the full amount of the goods and services input tax credit. Previously, the reimbursement was limited to a reduced rate. The recovered taxes are presented as deferred contributions until their allocation by management.

NOTES TO FINANCIAL STATEMENTS (continued)
Year ended March 31, 2010

6. Deferred contributions related to capital assets:

Deferred contributions related to capital assets represent the unamortized amount of contributions received for the purchase of capital assets. The amortization of such contributions is recorded as revenue in the statement of operations. The changes in balances of the deferred contributions are as follows:

	2010	2009
Opening balance	$3,792,392	$4,600,912
Add allocation of funding for capital asset purchases	1,059,076	1,624,839
Less amount amortized to revenues	(3,628,574)	(2,433,359)
Ending balance	$1,222,894	$3,792,392

7. Supplemental information:

	2010	2009
Statement of operations:		
Investment income:		
Interests	$447,634	$826,429
Dissolution of Émerillon Thérapeutiques	241,070	—
	$688,704	$826,429
Revenues from intellectual property and others:		
Contribution – Financed expenses of the Innovation center	$194,000	$ —
Intellectual property	10,657	—
	$204,657	$ —
Statement of cash flows:		
Non monetary transactions from the variance of deferred contributions:		
Amount transferred to deferred contributions related to capital assets	$(1,059,076)	$(1,624,839)
Amount reclassified as contribution to be reimbursed	—	278
	$(1,059,076)	$(1,624,561)

8. Financial instruments:

Fair value, credit risk and interest rate:

The Corporation determined that the book value of its short-term financial assets and liabilities, including cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities, approximates their fair value due to the short-term nature of these instruments.

The credit risk arises from the possibility of financial loss caused by the inability of a party to fulfill its contractual obligation. The Corporation performs ongoing monitoring of its risk exposure and takes appropriate actions to reduce the probability that such risk leads to losses.

NOTES TO FINANCIAL STATEMENTS (continued)
Year ended March 31, 2010

8. Financial instruments (continued)**:**

Financial instruments that could expose the Corporation to important credit risk mainly consist of its investment in bonds. The Corporation's investment policy has been established to secure and protect capital so that current and future cash flow requirements can be met.

Bond investments consist primarily of fixed income securities issued by governmental and municipal organizations granted high credit rating. The weighted average yield at cost, considering that the bond is held to maturity, is 2.32%.

9. Commitments:

In accordance with agreements entered into with Genome Canada with regard to a financial support commitment of $91,846,788 related to the Applied Genomics and Proteomics Research in Human Health, to Competition III, to the International Consortium Initiatives ("ICI") and to New Technology Development ("Tecdev") and Competition ABC, the Corporation has agreed, among other things, to obtain equivalent financing commitments from other parties. In this matter, financial commitments from the Government of Québec amounted to $59,090,742 and an amount of $59,244,997 is committed from other parties, of which no amount remains to be finalized.

In accordance with agreements entered into with the Government of Québec regarding a financial support of $48,000,000 related to the Privac Competition, Research Competition, to strategic initiatives and to administrative center costs, the Corporation has agreed to obtain financing commitments from other parties in the amount of $20,759,768, in regards to the Privac Competition, of which no amount remains to be finalized.

The Corporation's research projects portfolio totals $152,396,637. As of March 31, 2010, the residual balance for these projects totals $64,332,162.

The Corporation entered into various agreements for services, rents and purchase of consumables and capital assets. These agreements expire at various dates until 2012. The payments under these agreements for the coming years are: $851,787 in 2011 and $860,157 in 2012.

10. Subsequent event:

As at April 19, 2010, Génome Québec has transferred the pharmacogenomics center to the Montréal Heart Institute. An amount of $525,449 was paid to the buyer representing the residual balance of the Technology investment and contingency fund of this Center at this date plus the restricted capital assets with a net book value of $19,472. Finally, the accounts receivable at the effective date will be cashed by Génome Québec and the accounts payable and accrual will be paid by Génome Québec representing an amount of $155,558 and $145,321, respectively, as at March 31, 2010.

11. Comparative figures:

Certain comparative figures for 2009 have been reclassified in order to conform with the financial statement presentation adopted in 2010.

MEMBERS OF THE BOARD OF DIRECTORS AND COMMITTEES
Génome Québec

BOARD OF DIRECTORS

Chairman of the Board
- **Gérald A. Lacoste**, Q.C.
  Corporate Director

Vice-Chairman of the Board
- **Jean-Claude Cadieux**, PhD
  Management Consultant

Secretary-Treasurer of the Board
- **Jean Brunet**, Lawyer
  Stein Monast L.L.P.

BOARD MEMBERS
- **Daniel Bouthillier**, PhD, MBA
  Executive Director, Global Site Services, Merck Frosst
- **Hélène Desmarais**
  Chairman of the Board and Chief Executive Officer
  Centre d'entreprises et d'innovation de Montréal (CEIM)
- **Jean-Paul Gagné**
  Publisher Emeritus, Journal Les Affaires
- **Yves Joanette**, PhD, FCAHS
  President and CEO, Fonds de la recherche en santé du Québec (FRSQ)
- **Pierre Prémont**, PhD, FCA
  President and CEO, Fonds québécois de la recherche sur la nature et les technologies (FQRNT)
- **Jean-Marc Proulx**, Eng., MBA
  President and CEO, Génome Québec
- **Louise Proulx**, PhD
  Vice President, Vertex Pharmaceutiques (Canada) Inc.
- **Jacques Remacle**
  Principal Scientific Officer, Genomics and Systemic Biology Unit, European Commission, Brussels
- **Luc Tanguay**, MSc, CFA
  Senior Executive Vice President and CFO, Theratechnologies Inc.

OBSERVERS
- **Dale Patterson**
  Vice President, External Relations, Génome Canada
- **Geneviève Tanguay**, PhD
  Assistant Deputy Minister, Ministère du Développement économique, de l'innovation et de l'exportation (MDEIE)

EXECUTIVE COMMITTEE

Chairman of the Committee
- **Gérald A. Lacoste**, Q.C.
  Corporate Director

Secretary of the Committee
- **Jean Brunet**, Lawyer
  Stein Monast L.L.P.
- **Jean-Claude Cadieux**, PhD
  Management Consultant
- **Jean-Marc Proulx**, Eng., MBA
  Génome Québec
- **Luc Tanguay**, MSc, CFA
  Theratechnologies Inc.

GOVERNANCE COMMITTEE

Chairman of the Committee
- **Jean-Paul Gagné**
  Journal Les Affaires

Secretary of the Committee
- **Jean Brunet**, Lawyer
  Stein Monast L.L.P.
- **Daniel Bouthillier**, PhD, MBA
  Merck Frosst
- **Gérald A. Lacoste**, Q.C.
  Corporate Director
- **Pierre Prémont**, PhD, FCA
  Fonds québécois de la recherche sur la nature et les technologies (FQRNT)
- **Jean-Marc Proulx**, Eng., MBA
  Génome Québec

AUDIT/INVESTMENT COMMITTEE

Chairman of the Committee
- **Luc Tanguay**, MSc, CFA
  Theratechnologies Inc.
- **Jean-Claude Cadieux**, PhD
  Management Consultant
- **Jean-Paul Gagné**
  Journal Les Affaires

STRATEGIC AND SCIENTIFIC ADVISORY BOARD (SSAB)

Chairman of the SSAB
- **Camille Limoges**, PhD
- **Jo Bury**, PhD, MBA
  VIB
- **Michel Georges**, PhD
  Université de Liège
- **Mark McCarthy**, PhD
  Wellcome Trust, Oxford
- **Teri Manolio**, MD, PhD
  National Institutes of Health (NIH)

MEMBERS OF PARTNER FORUM AND EMPLOYEES
Génome Québec

PARTNER FORUM

- **Jacques Babin**, MSc
  Fonds québécois de la recherche sur la société et la culture (FQRSC)
- **Jacques Beauvais**, PhD
  Université de Sherbrooke
- **Edwin Bourget**, PhD
  Université Laval
- **Louise Dandurand**, PhD
  Université Concordia
- **Joseph Hubert**, PhD
  Université de Montréal
- **Yves Joanette**, PhD, FCAHS
  Fonds de la recherche en santé du Québec (FRSQ)
- **Pierre Prémont**, PhD, FCA
  Fonds québécois de la recherche sur la nature et les technologies (FQRNT)
- **Geneviève Tanguay**, PhD
  Ministère du Développement économique, de l'innovation et de l'exportation (MDEIE)
- **Rima Rozen**, PhD
  Université McGill

GÉNOME QUÉBEC EMPLOYEES

Amr Al Mallah
Anne-Marie Alarco
Yolaine Ancellin
Steve Arsenault
Lucian Avram
François Marie Bacot
Guillaume Barreau
Yolande Bastien
Christopher Beck
Alexandre Bélisle
Line Benguerel
Denis Bilodeau
Michal Blazejczyk
Daniel Boismenu
Julie Boudreau
Marc Bouffard
Marie-Kym Brisson
Sébastien Brunet
David Bujold
Alice Carey
Emmanuelle Cartier
Raymond Castonguay
Valérie Catudal
Christine Cellier
Fanny Chagnon
Marie-Paule Choquette
Cristina Ciurli
Catherine Côté
Geneviève Dancausse
Marcos Di Falco
Joana Dias
Jacqueline Dionne
Christian Drouin
Anick Dubois
Mathieu Durand
Nathalie Émond
Isabelle Fillion
Joëlle Fontaine
Nancy Fournier
Pierre Francoeur
Rosalie Fréchette
Julie Gagné
Marie-Josée Gaulin-Marion
Geneviève Geneau
Steve Geoffroy
Claire Goguen
Paul Guelpa
Isabelle Guillet
Nathalie Hamel
Cecilia Hernandez
Abdelmadjid Hihi
Louis Dumond Joseph
Éva Kammer
Amélie Kirouac
André Laberge
Sylvie Laboissière
Marc-André Labonté
Philippe Laflamme
Claude Lamarre
Nancy Lambert
Claire Landry
Mathieu Langlois
Fabienne Lefebvre
Pierre Lepage
Darie Lessard
Louis Létourneau
Gary Leveque
Catalina Lopez Correa
Stéphanie Lord-Fontaine
Lizette Mailloux
Yannick Marcon
Aurélie Masurel
Philippe-Antoine Ménard
Jana Mickova
Nancy Milot
Ian Mongrain
Alexandre Montpetit
Thuong Ngo
Valérie Normand
Line Pelosse
Daniel Pépin
Julie Perrone
André Ponton
Jean-Marc Proulx
Sylvie Renaud
Yannick Renaud
Yannick Richard
Lyne Robert
Frédérick Robidoux
Sharen Sophie Roland
Line Roy
Lorraine Saule
Laura Sbarra
Donna Sinnett
Andrea Smith
Dennis Spathis
Alfredo Staffa
Daniel Tessier
Marie-Catherine Tessier
Louise Thibault
Philippe Thibault
Vincent Trudel
Julie Vallée
Diane Valois
Tu Linh Van
Tibor Van Rooij
Sylvain Versailles
Daniel Vincent
Hao Fan Yam
Chung-Yan Yuen
Nathalie Zapata
Corine Zotti

RETOMBÉES DES GRANDS PROJETS / LARGE SCALE PROJECT OUTCOMES
Décembre 2009 / December 2009

	Nombre de personnes employées au 3e trimestre 2009-2010	Nombre de chercheurs formés au 3e trimestre 2009-2010	Nombre de publications acceptées ou soumises	Nombre de conférences à titre de conférencier	Nombre de déclarations d'inventions ou de brevets	Date de début du projet
	Number of persons employed in the 3rd quarter 2009-2010	Number of scientists trained in the 3rd quarter 2009-2010	Number of publications accepted or submitted	Number of conferences as speaker	Number of declarations of inventions or patents	Project starting date
CONCOURS III/COMPETITION III						
Sherif Abou Elela – FAEASI	14	2	9	24	3	Janvier/ January 2006
Ken Dewar – Singe Vervet/Vervet Monkey	4,5	2	2	4	0	Janvier/ January 2006
Thomas Hudson – GRID	43	13	66	32	2	Avril/April 2006
Guy Rouleau – S2D	22	2	3	12	1	Avril/April 2006
Jean-Claude Tardif – Pharmacogénomique/ Pharmacogenomics	28	8	6	34	0	Avril/April 2006
John MacKay – Arborea II	40	13	28	87	0	Avril/April 2006
Total	**151,5**	**40**	**114**	**193**	**6**	
INITIATIVE DE CONSORTIUM INTERNATIONAL/INTERNATIONAL CONSORTIUM INITIATIVE						
Bartha Maria Knoppers – Thomas Hudson P3G/CaG	31,66	18	28	50	0	Avril/April 2007
Total	**31,66**	**18**	**28**	**50**	**0**	
CONCOURS PRIVAC/PRIVAC COMPETITION						
Daniel Lamarre/Sylvain Meloche Plateforme ARNi	7	0	0	1	0	Janvier/ January 2008
Rafick-Pierre Sékaly – Plateforme NIML	18	3	2	4	2	Mai/May 2009
Michel G. Bergeron – GPOCT	13	2	1	16	0	Janvier/ January 2008
Michael Phillips – Jean-Claude Tardif Via-PGX	6,5	0	0	3	0	Octobre/ October 2007
Total	**44,5**	**5**	**3**	**24**	**2**	
CONCOURS DÉVELOPPEMENT TECHNOLOGIQUE/TECHNOLOGY DEVELOPMENT COMPETITION						
Maryam Tabrizian – DevTab	8,7	8	17	9	1	Juillet/July 2008
Rafick-Pierre Sékaly/Ryan Brinkman DevSek	4	1	1	2	0	Juillet/July 2008
Total	**12,7**	**9**	**18**	**11**	**1**	
CONCOURS ABC/ABC COMPETITION						
Thomas Bureau – VEGI	4	2	0	0	0	Octobre/ October 2009
Adrian Tsang – Genozymes	25	6	0	5	0	Octobre/ October 2009
Peter Facchini – Vincent Martin Phytometacyn	14,9	4	0	1	0	Octobre/ October 2009
Richard Gold – VALGEN	1	1	1	2	0	Octobre/ October 2009
Total	**44,9**	**13**	**1**	**8**	**0**	
TOTAL CONCOURS (projets en cours) COMPETITION TOTAL (projects in progess)	**285,26**	**85**	**164**	**286**	**9**	

BILAN DES PROJETS TERMINÉS / ASSESSMENT OF COMPLETED PROJECTS
Décembre 2009 / December 2009

	Nombre de personnes employées en année-personne / Number of persons employed in year-person	Nombre de chercheurs formés en année-personne / Number of scientists trained in year-person	Nombre de publications acceptées ou soumises / Number of publications accepted or submitted	Nombre de conférences à titre de conférencier / Number of conferences as speaker	Nombre de déclarations d'inventions ou de brevets / Number of declarations of inventions or patents	Durée du projet / Project duration
CONCOURS I & II, SANTÉ/ COMPETITIONS I & II, HEALTH						
Michel G. Bergeron – Technologies Theranostiques/Theranostic Technologies	118	25	25	58	11	3,25 ans/years
Deming Xu – Chimiogénomique/ Chemogenomics	32	2	8	4	1	3 ans/years
Thomas Hudson – ARCTIC	42	6	19	15	9	3,25 ans/years
Franz Lang – PEP Québec	49	21	20	18	0	3,5 ans/years
Bussey/Michnick – Organismes modèles/ Model Organisms	20	4	18	55	0	4 ans/years
John Bergeron – Protéomique/Proteomics	174	67	42	125	7	4 ans/years
Fernand Labrie – Atlas	347	120	49	29	2	5 ans/years
Bartha Maria Knoppers – GEDS	38	20	83	153	0	4 ans/years
Fathey Sarhan – Stress Abiotique Québec/ Abiotic Stress Québec	82	28	11	17	0	4 ans/years
Thomas Hudson – Génétique régulatrice/ Regulatory Genetics	117	27	16	51	6	4 ans/years
Rafick-Pierre Sékaly – S2K	194	79	17	150	6	4 ans/years
Mario Filion – IGWH	36	5	1	10	4	3 ans/years
Sherif Abou Elela – MoNa	51	8	6	9	2	3 ans/years
Adrian Tsang – Enzymes fongiques/ Fungal Enzymes	167	69	16	22	8	3 ans/years
Benoît Coulombe – Réseau de régulation/ Regulatory Networks	189	63	15	111	0	3,5 ans/years
John MacKay – Arborea I	98	31	23	63	2	3,5 ans/years
Thomas Hudson – Haplotype	34	2	14	87	1	3 ans/years
Emil Skamene – Souris congéniques/ Congenic Mice	60	13	2	11	3	4,25 ans/years
Guy Rouleau – Canaux ioniques/ Ionic Channels	40	5	0	16	3	4,25 ans/years
Terry Roemer – Candida albicans	51	0	2	3	3	3 ans/years
Barry Posner – Diabète de Type 2/T2DM	5	0	25	35	6	Octobre/ October 2004
Bartha Maria Knoppers – GPH	5	4	22	47	0	Janvier/ January 2006
TOTAL CONCOURS TERMINÉS/ TOTAL COMPLETED PROJECTS	**1949**	**599**	**434**	**1089**	**74**	